Global Hospital Care Partnering 2014 to 2020 provides the full collection of Hospital Care disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
Trends in Hospital Care partnering deals Financial deal terms for headline, upfront and royalty by stage of development Hospital Care partnering agreement structure Hospital Care partnering contract documents Top Hospital Care deals by value Most active Hospital Care dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Hospital Care disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Hospital Care deals.
The report presents financial deal terms values for Hospital Care deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Hospital Care dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Hospital Care dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Hospital Care deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Hospital Care dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Hospital Care deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Hospital Care partnering deals by specific Hospital Care target announced since 2014. The chapter is organized by specific Hospital Care therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Hospital Care partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Hospital Care partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Hospital Care technologies and products.
Report scope Global Hospital Care Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Hospital Care trends and structure of deals entered into by leading companies worldwide.
Global Hospital Care Partnering 2014 to 2020 includes: Trends in Hospital Care dealmaking in the biopharma industry since 2014 Analysis of Hospital Care deal structure Access to headline, upfront, milestone and royalty data Access to hundreds of Hospital Care deal contract documents Comprehensive access to over 950 Hospital Care deal records The leading Hospital Care deals by value since 2014 Most active Hospital Care dealmakers since 2014
The report includes deals for the following indications: Accident and emergency, Rehabilitation medicine, Surgery, Orthopedics, Aesthetic procedures, Transplantation, plus other hospital care indications.
In Global Hospital Care Partnering 2014 to 2020, available deals and contracts are listed by: Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component type Technology type Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Hospital care Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 950 hospital care deals. Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are the sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
Interventional Radiology - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Interventional Radiology - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Interventional Radiology pipeline products with comparative analysis of...
The Global Genomics Partnering Terms and Agreements 2014 to 2020 report provides an understanding and access to the Genomics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Genomics partnering deals Disclosed headlines, upfronts, milestones and royalties by stage...
Presbyopia - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H1 2020, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape. Presbyopia is an eye condition in which eye slowly loses the ability...
225 pages •
By Asia Market Information & Development Company
• May 2020
China’s demand for HIV Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption...
Blood Purification Equipment - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Blood Purification Equipment - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Blood Purification Equipment pipeline products with comparative...
Opioid Use Disorder - Epidemiology Forecast to 2028 Summary Opioid use disorder (OUD) is defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) as a problematic pattern of opioid use leading to clinically significant impairment or distress. Symptoms of OUD include...
The Global In Vitro Diagnostics Partnering Terms and Agreements 2014-2020 report provides a detailed understanding and analysis of how and why companies enter in vitro diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. This...
Smoothened Homolog - Pipeline Review, H1 2020 Summary Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 14 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The latest report Smoothened Homolog –...
Transthyretin - Pipeline Review, H1 2020 Summary Transthyretin (ATTR or Prealbumin or TBPA or TTR) – Transthyretin is a transport protein. It transports thyroid hormones in the plasma and cerebrospinal fluid, and also transports retinol (vitamin A) in the plasma. The diseases caused by mutations...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.